Therefore, the findings support the hypothesis that aberrant SETD5 upregulation reactivates the transcription of stem cell marker genes via SETD5-mediated chromatin reprogramming, resulting in cancer cells gaining stemness. The gene discussed is SETD5; the disease is cancer.